27 Jul 4DMT
David Kirn, M.D., Co-Founder and CEO
Oct. 11 | 5:45pm | Aseptic Technologies Ballroom
Emeryville, CA
(NASDAQ: FDMT)
4DMT is a clinical-stage biotherapeutics company harnessing the power of directed evolution for genetic medicines targeting large market diseases. 4DMT seeks to unlock the full potential of genetic medicines using its proprietary invention platform, Therapeutic Vector Evolution, which combines the power of the Nobel Prize-winning technology, directed evolution, with approximately one billion synthetic AAV capsid-derived sequences to invent customized and evolved vectors. The 4DMT customized and evolved vectors were invented for low dose delivery via clinically routine, well-tolerated, and minimally invasive routes of administration, and efficient transduction of cells in target tissues, with reduced immunogenicity and resistance to pre-existing antibodies. 4DMT is currently advancing five product candidates in clinical development: 4D-150 for wet AMD and DME, 4D-710 for cystic fibrosis lung disease, 4D-310 for Fabry disease cardiomyopathy, 4D-125 for XLRP, and 4D-110 for choroideremia. The 4D preclinical product candidates in development are: 4D-175 for geographic atrophy and 4D-725 for AATLD.
